Neurocrine Biosciences Quarterly Cash Flow Statement
NASDAQ: NBIXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Neurocrine Biosciences free cash flow
In the quarter ended Jun 30, 2026, Neurocrine Biosciences generated $136.4 million of operating cash flow and spent $7.8 million on capital expenditures. That left free cash flow of $128.6 million, a free-cash-flow margin of 13.4% of revenue. Free cash flow was up 43.7% from the prior year's $89.5 million.
Neurocrine Biosciences returned $12.0 million to shareholders through share repurchases, equal to 9% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Neurocrine Biosciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 144.40M | 197.90M | 153.70M | 209.50M | 107.50M | 7.90M | 103.10M | 129.80M | 65.00M | 43.40M | 147.70M | 83.10M |
| Net Income growth (YoY) | +34.33% | +2405.06% | +49.08% | +61.40% | +65.38% | -81.80% | -30.20% | +56.20% | -31.94% | — | +65.96% | +21.31% |
| Depreciation & Amortization | 8.40M | 7.20M | 6.40M | 6.70M | 6.30M | 6.60M | 6.20M | 5.60M | 6.40M | 5.30M | 4.90M | 4.60M |
| Stock-Based Compensation | 65.00M | 57.20M | 58.60M | 53.70M | 52.80M | 52.80M | 66.40M | 41.50M | 43.10M | 44.50M | 38.10M | 47.80M |
| Change in Working Capital | -99.30M | -91.40M | 111.50M | -73.00M | -62.50M | -41.60M | 67.70M | 28.00M | -82.40M | -28.80M | -120.60M | 96.90M |
| Operating Cash Flow | 136.40M | 145.80M | 388.40M | 227.50M | 102.00M | 64.80M | 242.50M | 158.00M | 64.60M | 130.30M | 123.50M | 212.00M |
| Capital Expenditures | -7.80M | -9.10M | 2.40M | -13.20M | -12.50M | -10.70M | -7.30M | -8.10M | -11.60M | -11.20M | -5.40M | -7.60M |
| Investing Cash Flow | -135.40M | -506.20M | -52.90M | -196.70M | -29.00M | 14.20M | -68.30M | 24.70M | -28.20M | -55.00M | -201.80M | -97.30M |
| Share Repurchases | -12.00M | -54.00M | 0 | 0 | -17.70M | -150.00M | -300.00M | 0 | 0 | 0 | — | — |
| Financing Cash Flow | 63.40M | -86.10M | 37.30M | 45.60M | -3.30M | -117.90M | -290.00M | 26.40M | -293.00M | 69.90M | 35.40M | 18.80M |
| Net Change in Cash | 64.40M | -446.50M | 372.80M | 76.20M | 69.90M | -38.90M | -116.10M | 209.40M | -256.60M | 145.20M | -42.60M | 133.50M |
| Free Cash Flow | 128.60M | 136.70M | 390.80M | 214.30M | 89.50M | 54.10M | 235.20M | 149.90M | 53.00M | 119.10M | 118.10M | 204.40M |
This table shows 12 quarterly periods of Neurocrine Biosciences's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NBIX's reporting calendar. What is a cash flow statement?